Ongoing clinical trials from other countries that mirror the SPRINT protocol, or conducted among hypertensive patients excluded from or not robustly represented in SPRINT, could provide additional evidence. In hypertension patients with diabetes, additional data from RCTs may be available in the next few years as two large trials, Blood Pressure Control Target in Diabetes (BPROAD) and Intervention for High-normal or Borderline-elevated Blood Pressure in Adults with Type 2 Diabetes (IPAD) are currently enrolling in China. These trials should provide further evidence for the benefit of specific SBP thresholds and goals in patients with diabetes. Recommendation 7. For patients 60 years and over, we recommend treating to a systolic blood pressure goal of <150 mm Hg with added benefit to lowering systolic blood pressure further for those between 130 mm Hg and 150 mm Hg. (Strong for | Reviewed, Amended) Discussion Among people age 60 and over with moderate to severe HTN, there is evidence that treating to an SBP goal of 150 mm Hg or less reduces cardiovascular morbidity and mortality. This strong recommendation is based on evidence from RCTs that compared a more intensive HTN strategy with placebo or a standard or less intensive strategy. The SR by Weiss et al. (2017) considered adults age 60 and over from 21 RCTs, nine of which specifically included individuals with an SBP of 160 mm Hg or higher.[56] Improved cardiovascular outcomes were seen among those given more intensive therapy targeting an SBP less than 150 mm Hg. Among people 60 years and over, there was also evidence of further benefit in lowering systolic blood pressure to levels between 130 and 150 mm Hg.[56] The SR by Ettehad et al. (2016) included 78 studies comparing HTN treatment to placebo and 14 studies comparing intensive HTN therapy to standard treatment. 